INTRODUCTION:
One of the most devastating complications after prosthetic breast reconstruction is infection. In the literature the infection rate of breast reconstruction using an implant device after mastectomy ranges between 1 to 35%.
1,2 Antibiotic treatment is the most conservative management but has inconsistent results: successful salvage without removal or exchange of the device ranges from 0 to 25%.
3 Currently, there are no detailed guidelines for antibiotics or protocol for the type of antibiotic, duration of treatment, or route of administration.
PURPOSE:
The primary aim of this study was to determine the effectiveness of a combination antibiotic protocol to treat breast prosthetic infections in mastectomy patients. Secondary aims included the identification of risk factors in patients who failed antibiotic salvage.
METHODS:
A protocol for all breast implant infections was instituted. Patients with clinical signs of infection were placed on intravenous piperacillin/tazobactam and daptomycin for 3 weeks. If patients did not respond or had progression of infection then the prosthetic device was removed. A single institution retrospective chart review evaluated procedures completed from 1/1/2014 to 5/15/2015 at Roswell Park Cancer Institute.
RESULTS:
Nineteen mastectomies followed by breast prosthetic reconstruction were identified in the study. The mean surgical age was 48.7 years (SD +/-9.2). Of the nineteen procedures, 9 had sentinel node biopsies and 1 underwent axillary node dissection. Subgroup analysis reveals majority of procedures resulting in a breast infection were patients who were current or previous smokers and either overweight or obese. Mean days to infection from surgery date were 29.0 days. The majority of the patients, 84.2% (16/19), had complete resolution of the infection. Patients without resolution of their infection, 15.8% (3/19) had their prosthetic devices removed. Mean and median duration of follow-up was 327.6 days (SD 78.28) and 332 days (range 196-493), respectively.
CONCLUSION:
Implementation of a standardized antibiotic protocol of piperacillin/tazobactam and daptomycin resulted in a prosthetic device salvage rate of 84% in post mastectomy patients. This result is the highest salvage in post mastectomy patients. The early institution of an antibiotic protocol as conservative management for treatment of breast implant infections was effective in this cohort of patients. 
METHODS:
A retrospective record review was conducted. Patient data were extracted from the electronic medical record by means of manual review and stored in a database. Adult patient records were included for analysis if the patient underwent a mastectomy followed by immediate or delayed expander reconstruction, had infection of at least one pocket confirmed via culture, had received oral and systemic antibiotics for at least one week, and subsequently received NPWTid. All procedures were completed between January 1, 2016 and February 1, 2017. Demographics, surgical approach, comorbidities and expander salvage rate were recorded and analyzed.
Six female patients with a median age of 50.8 were included in the analysis. Five of 6 patients had undergone sub-pectoral expander reconstruction and one patient received pre-pectoral expander reconstruction. Antibiotics were also continued based on specific cultures. All surgical site infections were thoroughly debrided and irrigated. Adjunctive NPWTi-d was initiated: instillation of a polyhexanide solution with a 20-minute dwell time, followed by 3.5 hours of -125 mmHg negative pressure. Duration of therapy ranged from 1-3 days.
RESULTS:
Salvage of the expander was achieved in all 6 patients. None of the pockets showed signs of infection after application of NPWTi-d. Healthy granulation tissue was present in all NPWTi-d treated pockets. All breast incisions were successfully closed with good cosmetic results and without further sequelae.
CONCLUSION:
Tissue expanders could be salvaged in all 6 patients with SSOs in this series who received NPWTi-d. This small sample size does not allow for a reliable extrapolation to the general population. Although further studies are needed, the results from these 6 patients suggest that NPWTi-d may represent an important new adjunctive therapy option in device salvage for breast reconstruction patients.
